- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting epigenetics in sarcomas through EZH2 inhibition
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-08
DOI
10.1186/s13045-020-00868-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
- (2019) Daisuke Ennishi et al. Cancer Discovery
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- 1892OMolecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)
- (2018) S Daigle et al. ANNALS OF ONCOLOGY
- 1612PDA phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
- (2018) R L Jones et al. ANNALS OF ONCOLOGY
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin inp53mutant gastric cancer cells
- (2014) J. Bai et al. CELL PROLIFERATION
- A rationale to target the SWI/SNF complex for cancer therapy
- (2014) Anja F. Hohmann et al. TRENDS IN GENETICS
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers
- (2012) Ryan S. Lee et al. JOURNAL OF CLINICAL INVESTIGATION
- Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions
- (2012) Lisa M Sullivan et al. MODERN PATHOLOGY
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells
- (2012) Irina Alimova et al. NEURO-ONCOLOGY
- Trends in survival for patients with metastatic soft-tissue sarcoma
- (2010) Antoine Italiano et al. CANCER
- Loss of INI1 Expression is Characteristic of Both Conventional and Proximal-type Epithelioid Sarcoma
- (2009) Jason L. Hornick et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now